This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Twelves, C. Search for Related Content PubMed PubMed Citation Articles by Twelves, C.

Vision of the Future: Capecitabine

Cancer Research Campaign Department of Medical Oncology, University of Glasgow, and Beatson Oncology Centre, Glasgow, United Kingdom

Correspondence: Chris Twelves, M.D., Beatson Oncology Centre, Western Infirmary, Glasgow, G11 6NT, United Kingdom. Telephone: 44-141-211-1712; Fax: 44-141-211-1869; e-mail: c.twelves{at}beatson.gla.ac.uk

Capecitabine is a thymidine phosphorylase (TP)-activated oral fluoropyrimidine, rationally designed to generate 5-fluorouracil (5-FU) preferentially within tumors. This tumor selectivity is achieved through exploitation of the significantly higher activity of TP in tumor compared with healthy tissue. The high single-agent activity of capecitabine in breast and colorectal cancer suggests that capecitabine may have a role in the treatment of other tumor types that are sensitive to 5-FU, such as pancreatic cancer. Tumor types known to have a high level of TP activity, such as renal cancer, are especially attractive targets for capecitabine therapy. Capecitabine has potential as monotherapy in these tumor types, or as a combination partner for other cytotoxic agents with different mechanisms of action and little overlap of key toxicities. In particular, some cytotoxic drugs, such as the taxanes and cyclophosphamide, are known to upregulate TP activity in tumor tissue, offering the potential for synergistic action. The combination of capecitabine and docetaxel has demonstrated significant activity in women with anthracycline-pretreated breast cancer, and is the only cytotoxic combination to significantly increase survival compared with standard therapy in this setting. In addition, capecitabine as monotherapy or in combination with other cytotoxic agents has shown encouraging activity in pancreatic, ovarian, and renal cell cancers. This article discusses recent data from clinical trials investigating capecitabine in a range of tumor types, highlighting the potential future role of capecitabine as an alternative to traditional i.v. chemotherapy.

Key Words. Capecitabine • 5-FU • Thymidine phosphorylase • Breast cancer • Pancreatic cancer • Ovarian cancer • Renal cell cancer

This article has been cited by other articles:

				B. T. Hennessy, A. M. Gauthier, L. B. Michaud, G. Hortobagyi, and V. Valero Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature Ann. Onc., August 1, 2005; 16(8): 1289 - 1296. [Abstract] [Full Text] [PDF]

				H. Seeliger, M. Guba, G. E. Koehl, A. Doenecke, M. Steinbauer, C. J. Bruns, C. Wagner, E. Frank, K.-W. Jauch, and E. K. Geissler Blockage of 2-Deoxy-D-Ribose-Induced Angiogenesis with Rapamycin Counteracts a Thymidine Phosphorylase-Based Escape Mechanism Available for Colon Cancer under 5-Fluorouracil Therapy Clin. Cancer Res., March 1, 2004; 10(5): 1843 - 1852. [Abstract] [Full Text] [PDF]

				R. D. Petty, M. C. Nicolson, S. Skaria, T. S. Sinclair, L. M. Samuel, and M. Koruth A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity Ann. Onc., July 1, 2003; 14(7): 1100 - 1105. [Abstract] [Full Text] [PDF]